Literature DB >> 32366470

Additional safety consideration for azithromycin in the management of SARS-CoV-2 infection.

Matthew D Seftel1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32366470      PMCID： PMC7207176          DOI： 10.1503/cmaj.75427

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  2 in total

Review 1.  Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.

Authors:  David N Juurlink
Journal:  CMAJ       Date:  2020-04-08       Impact factor: 8.262

2.  Effect of Azithromycin on Airflow Decline-Free Survival After Allogeneic Hematopoietic Stem Cell Transplant: The ALLOZITHRO Randomized Clinical Trial.

Authors:  Anne Bergeron; Sylvie Chevret; Angela Granata; Patrice Chevallier; Laure Vincent; Anne Huynh; Reza Tabrizi; Hélène Labussiere-Wallet; Marc Bernard; Sylvain Chantepie; Jacques-Olivier Bay; Anne Thiebaut-Bertrand; Sylvain Thepot; Nathalie Contentin; Luc-Matthieu Fornecker; Natacha Maillard; Karine Risso; Ana Berceanu; Didier Blaise; Regis Peffault de La Tour; Jason W Chien; Valérie Coiteux; Gérard Socié
Journal:  JAMA       Date:  2017-08-08       Impact factor: 56.272
  2 in total
  2 in total

Review 1.  Metabolism and Interactions of Chloroquine and Hydroxychloroquine with Human Cytochrome P450 Enzymes and Drug Transporters.

Authors:  Slobodan Rendic; Frederick Peter Guengerich
Journal:  Curr Drug Metab       Date:  2020       Impact factor: 3.731

Review 2.  The HMOX1 Pathway as a Promising Target for the Treatment and Prevention of SARS-CoV-2 of 2019 (COVID-19).

Authors:  Neelu Batra; Cristabelle De Souza; Jyoti Batra; Alan G Raetz; Ai-Ming Yu
Journal:  Int J Mol Sci       Date:  2020-09-03       Impact factor: 5.923
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.